Karun V Sharma1, Pavel S Yarmolenko2, Haydar Celik2, Avinash Eranki2, Ari Partanen3, Anilawan Smitthimedhin4, Aerang Kim5, Matthew Oetgen6, Domiciano Santos7, Janish Patel7, Peter Kim2. 1. Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, Washington, DC; Division of Radiology, Children's National Medical Center, Washington, DC. Electronic address: kvsharma@childrensnational.org. 2. Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, Washington, DC. 3. Division of Clinical Science MR Therapy, Philips, Andover, MA. 4. Division of Radiology, Children's National Medical Center, Washington, DC. 5. Division of Oncology, Children's National Medical Center, Washington, DC. 6. Division of Orthopedics, Children's National Medical Center, Washington, DC. 7. Division of Anesthesiology, Children's National Medical Center, Washington, DC.
Abstract
OBJECTIVE: To evaluate clinical feasibility and safety of magnetic resonance imaging-guided high-intensity focused ultrasound (MR-HIFU) treatment of symptomatic osteoid osteoma and to compare clinical response with standard of care treatment. STUDY DESIGN: Nine subjects with radiologically confirmed, symptomatic osteoid osteoma were treated with MR-HIFU in an institutional review board-approved clinical trial. Treatment feasibility and safety were assessed. Clinical response was evaluated in terms of analgesic requirement, visual analog scale pain score, and sleep quality. Anesthesia, procedure, and recovery times were recorded. This MR-HIFU group was compared with a historical control group of 9 consecutive patients treated with radiofrequency ablation. RESULTS: Nine subjects (7 male, 2 female; 16 ± 6 years) were treated with MR-HIFU without technical difficulties or any serious adverse events. There was significant decrease in their median pain scores 4 weeks within treatment (6 vs 0, P < .01). Total pain resolution and cessation of analgesics were achieved in 8 of 9 patients after 4 weeks. In the radiofrequency ablation group, 9 patients (8 male, 1 female; 10 ± 6 years) were treated in routine clinical practice. All 9 demonstrated complete pain resolution and cessation of medications by 4 weeks with a significant decrease in median pain scores (9 vs 0, P < .001). One developed a second-degree skin burn, but there were no other adverse events. Procedure times and treatment charges were comparable between the 2 groups. CONCLUSION: This pilot study shows that MR-HIFU treatment of osteoid osteoma refractory to medical therapy is feasible and can be performed safely in pediatric patients. Clinical response is comparable with standard of care treatment but without any incisions or exposure to ionizing radiation. TRIAL REGISTRATION: ClinicalTrials.govNCT02349971.
OBJECTIVE: To evaluate clinical feasibility and safety of magnetic resonance imaging-guided high-intensity focused ultrasound (MR-HIFU) treatment of symptomatic osteoid osteoma and to compare clinical response with standard of care treatment. STUDY DESIGN: Nine subjects with radiologically confirmed, symptomatic osteoid osteoma were treated with MR-HIFU in an institutional review board-approved clinical trial. Treatment feasibility and safety were assessed. Clinical response was evaluated in terms of analgesic requirement, visual analog scale pain score, and sleep quality. Anesthesia, procedure, and recovery times were recorded. This MR-HIFU group was compared with a historical control group of 9 consecutive patients treated with radiofrequency ablation. RESULTS: Nine subjects (7 male, 2 female; 16 ± 6 years) were treated with MR-HIFU without technical difficulties or any serious adverse events. There was significant decrease in their median pain scores 4 weeks within treatment (6 vs 0, P < .01). Total pain resolution and cessation of analgesics were achieved in 8 of 9 patients after 4 weeks. In the radiofrequency ablation group, 9 patients (8 male, 1 female; 10 ± 6 years) were treated in routine clinical practice. All 9 demonstrated complete pain resolution and cessation of medications by 4 weeks with a significant decrease in median pain scores (9 vs 0, P < .001). One developed a second-degree skin burn, but there were no other adverse events. Procedure times and treatment charges were comparable between the 2 groups. CONCLUSION: This pilot study shows that MR-HIFU treatment of osteoid osteoma refractory to medical therapy is feasible and can be performed safely in pediatric patients. Clinical response is comparable with standard of care treatment but without any incisions or exposure to ionizing radiation. TRIAL REGISTRATION: ClinicalTrials.govNCT02349971.
Authors: Avinash Eranki; Navid Farr; Ari Partanen; Karun V Sharma; Christopher T Rossi; Avi Z Rosenberg; AeRang Kim; Matthew Oetgen; Haydar Celik; David Woods; Pavel S Yarmolenko; Peter C W Kim; Bradford J Wood Journal: Int J Hyperthermia Date: 2018-02-22 Impact factor: 3.914
Authors: Avinash Eranki; Priya Srinivasan; Mario Ries; AeRang Kim; Christopher A Lazarski; Christopher T Rossi; Tatiana D Khokhlova; Emmanuel Wilson; Susan M Knoblach; Karun V Sharma; Bradford J Wood; Chrit Moonen; Anthony D Sandler; Peter C W Kim Journal: Clin Cancer Res Date: 2019-10-15 Impact factor: 13.801
Authors: Michael S Bobola; Lucas Chen; Chikodinaka K Ezeokeke; Katy Kuznetsova; Annamarie C Lahti; Weicheng Lou; Aleksey N Myroniv; Nels W Schimek; Madison L Selby; Pierre D Mourad Journal: Curr Pain Headache Rep Date: 2018-07-10
Authors: Caitlin Tydings; Pavel Yarmolenko; Miriam Bornhorst; Eva Dombi; John Myseros; Robert Keating; James Bost; Karun Sharma; AeRang Kim Journal: Neurooncol Adv Date: 2021-08-18
Authors: Lazzaro di Biase; Emma Falato; Maria Letizia Caminiti; Pasquale Maria Pecoraro; Flavia Narducci; Vincenzo Di Lazzaro Journal: Neurol Res Int Date: 2021-06-29